Skip to content
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
4Statement of changes in beneficial ownership of securities2/22/20222/18/2022
8-KCurrent report2/15/20222/15/2022
8-KCurrent report2/15/20222/14/2022
10-QQuarterly report [Sections 13 or 15(d)]2/14/202212/31/2021
EFFECTNotice of Effectiveness2/11/2022
EFFECTNotice of Effectiveness2/11/2022
8-KCurrent report2/10/20222/10/2022
CORRESPCorrespondence2/10/2022
CORRESPCorrespondence2/9/2022
S-3/ARegistration statement under Securities Act of 1933 - amendment2/9/2022
UPLOADSEC-generated letter2/8/2022
UPLOADSEC-generated letter2/8/2022
SC 13G/AStatement of acquisition of beneficial ownership by individuals - amendment2/4/2022
S-3Registration statement under Securities Act of 19332/4/2022
S-3Registration statement under Securities Act of 19332/4/2022
4Statement of changes in beneficial ownership of securities1/24/20221/24/2022
4Statement of changes in beneficial ownership of securities1/24/20221/24/2022
4Statement of changes in beneficial ownership of securities1/24/20221/24/2022
4Statement of changes in beneficial ownership of securities1/24/20221/24/2022
4Statement of changes in beneficial ownership of securities1/24/20221/24/2022
4Statement of changes in beneficial ownership of securities1/24/20221/24/2022
8-KCurrent report1/19/20221/19/2022
4Statement of changes in beneficial ownership of securities1/6/20221/6/2022
8-KCurrent report1/5/20221/5/2022
4Statement of changes in beneficial ownership of securities12/30/202112/29/2021
4Statement of changes in beneficial ownership of securities12/30/202112/29/2021
4Statement of changes in beneficial ownership of securities12/30/202112/29/2021
4Statement of changes in beneficial ownership of securities12/30/202112/30/2021
4Statement of changes in beneficial ownership of securities12/30/202112/29/2021
8-K/ACurrent report - amendment12/22/202110/13/2021
  • « Previous
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 16
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • Articles and Videos
  • Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
  • The Evolving Alzheimer’s Disease Landscape

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*